Dermatology Reports
26 | concomitant therapy with ixekizumab plus tirzepatide in adults with psoriatic arthritis and overweight or obesity demonstrated superior disease control compared to ixekizumab alone: Results from the PH3B together-psa trial
By Associazione Dermatologi-Venereologi Ospedalieri Italiani e della Sanità Pubblica.
Abstract
Background. Overweight and obesity occurs in 72-82%[1,2] of patients with psoriatic arthritis (PsA) and is associated with worse clinical outcomes and increased comorbidities[3]. We evaluated efficacy and safety of ixekizumab and tirzepatide (IXE+TZP) compared to ixekizumab (IXE) in adults with active PsA and overweight (BMI>27-
Keywords
- Spondyloarthritis Studies and Treatments
- psoriatic arthritis
- ixekizumab
- tirzepatide
- combination therapy
- obesity
- overweight
- disease control
- anti-TNF therapy
- Open access
Source
Published in Dermatology Reports. The abstract is shown as published and remains the work of its authors; read the full article at the source.
Prognia lists this article for reference and education. It is not medical advice. Always read the original and follow current guidelines and local protocols before acting on it.